Orion Oyj B Total Assets
Orion Oyj B total assets. Based on the latest financial reports, Orion Oyj B (ORNBV) holds total assets worth €1.65 Billion EUR (≈ $1.92 Billion USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Orion Oyj B (ORNBV) total market value for the company's overall valuation and market capitalisation.
Total Assets of Orion Oyj B (2000–2024)
Total assets of Orion Oyj B from 2000 to 2024. This chart illustrates how Orion Oyj B's total assets have evolved over time, based on quarterly financial data. See latest Orion Oyj B stock price today for real-time trading data and today's change.
Orion Oyj B - Asset Composition Analysis
Orion Oyj B Total Assets Breakdown (December 2024)
Orion Oyj B total assets breakdown as of December 2024. Orion Oyj B's total assets of €1.65 Billion consist of 62.4% current assets and 37.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 12.6% |
| Accounts Receivable | €376.40 Million | 23.1% |
| Inventory | €418.60 Million | 25.7% |
| Property, Plant & Equipment | €417.60 Million | 25.6% |
| Intangible Assets | €87.90 Million | 5.4% |
| Goodwill | €87.20 Million | 5.4% |
Asset Composition Trend (2000–2024)
This chart illustrates how Orion Oyj B's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore ORNBV working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Orion Oyj B's current assets represent 62.4% of total assets in 2024, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 12.6% of total assets in 2024, up from 2.9% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, an increase from 6.0% in 2000.
- Asset Diversification: The largest asset category is inventory at 25.7% of total assets.
Orion Oyj B Competitors by Total Assets
Key competitors of Orion Oyj B based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Novartis AG
SW:NOVN
|
Switzerland | CHF118.89 Billion |
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.02 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$201.13 Billion |
|
Novartis AG
MX:NVSN
|
Mexico | MX$118.53 Billion |
|
Biogen Inc
NASDAQ:BIIB
|
USA | $32.09 Billion |
|
Organon & Co
NYSE:OGN
|
USA | $13.18 Billion |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019
|
China | CN¥12.85 Billion |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771
|
China | CN¥2.55 Billion |
Orion Oyj B - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.86 | 2.39 | 3.94 |
| Quick Ratio | 1.05 | 1.29 | 2.47 |
| Cash Ratio | 0.34 | 0.00 | 0.00 |
| Working Capital | €466.70 Million | €485.40 Million | €509.70 Million |
Orion Oyj B - Advanced Valuation Insights
This section examines the relationship between Orion Oyj B's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.30 |
| Latest Market Cap to Assets Ratio | 5.20 |
| Asset Growth Rate (YoY) | 13.2% |
| Total Assets | €1.63 Billion |
| Market Capitalization | $8.48 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Orion Oyj B's assets at a significant premium (5.20x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Orion Oyj B's assets grew by 13.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Orion Oyj B (2000–2024)
The table below shows the annual total assets of Orion Oyj B from 2000 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €1.63 Billion ≈ $1.90 Billion |
+13.24% |
| 2023-12-31 | €1.44 Billion ≈ $1.68 Billion |
-4.32% |
| 2022-12-31 | €1.50 Billion ≈ $1.76 Billion |
+34.97% |
| 2021-12-31 | €1.11 Billion ≈ $1.30 Billion |
-0.14% |
| 2020-12-31 | €1.12 Billion ≈ $1.30 Billion |
+7.71% |
| 2019-12-31 | €1.04 Billion ≈ $1.21 Billion |
-9.68% |
| 2018-12-31 | €1.15 Billion ≈ $1.34 Billion |
+8.64% |
| 2017-12-31 | €1.06 Billion ≈ $1.23 Billion |
-0.70% |
| 2016-12-31 | €1.06 Billion ≈ $1.24 Billion |
+1.48% |
| 2015-12-31 | €1.05 Billion ≈ $1.22 Billion |
+4.58% |
| 2014-12-31 | €1.00 Billion ≈ $1.17 Billion |
+2.30% |
| 2013-12-31 | €979.00 Million ≈ $1.14 Billion |
+16.98% |
| 2012-12-31 | €836.90 Million ≈ $978.42 Million |
+7.42% |
| 2011-12-31 | €779.10 Million ≈ $910.85 Million |
+4.47% |
| 2010-12-31 | €745.80 Million ≈ $871.92 Million |
+2.57% |
| 2009-12-31 | €727.10 Million ≈ $850.06 Million |
+4.54% |
| 2008-12-31 | €695.50 Million ≈ $813.11 Million |
+17.98% |
| 2007-12-31 | €589.50 Million ≈ $689.19 Million |
+0.24% |
| 2006-12-31 | €588.10 Million ≈ $687.55 Million |
-48.27% |
| 2005-12-31 | €1.14 Billion ≈ $1.33 Billion |
+0.11% |
| 2004-12-31 | €1.14 Billion ≈ $1.33 Billion |
-7.43% |
| 2003-12-31 | €1.23 Billion ≈ $1.43 Billion |
-12.99% |
| 2002-12-31 | €1.41 Billion ≈ $1.65 Billion |
+48.63% |
| 2001-12-31 | €948.50 Million ≈ $1.11 Billion |
+3.71% |
| 2000-12-31 | €914.60 Million ≈ $1.07 Billion |
-- |
About Orion Oyj B
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflam… Read more